EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cardiovascular morbidity and mortality in acromegaly-associated diabetes: a Swedish nationwide study

Angelo Milioto iD, Oskar Ragnarsson, Diego Ferone, Martin Adiels iD, J Gustav Smith, Annika Rosengren iD, Gudmundur Johannsson iD, Daniela Esposito iD

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgag322 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Angelo Milioto und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy, University of Gothenburg, 413 46 Gothenburg, Sweden. Hauptthemen laut MEDLINE: Acromegaly, Cardiovascular Diseases, Diabetes Mellitus, Type 2. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ALF, Svenska Sällskapet för Medicinsk Forskning, Åke Wiberg Stiftelse, Göteborgs läkaresällskap.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Secondary diabetes mellitus occurs in 30% to 50% of patients with acromegaly despite a lean phenotype, whereas type 2 diabetes mellitus (T2DM) is associated with adiposity.

Objective

We compared mortality, morbidity, and treatment patterns between patients with acromegaly-associated diabetes (ACRO-DM) and T2DM.

Design

Nationwide, retrospective, matched-cohort study in Sweden.

Methods

The ACRO-DM group included patients with an acromegaly diagnosis in the Patient Register, with diabetes registered in the National Diabetes Register (NDR) or a dispensed glucose-lowering drug in the Prescribed Drug Register. Controls with T2DM from the NDR were matched 10:1 for sex, age, calendar year, and diabetes duration. We derived mortality and morbidity outcomes from the Death and Patient Registers.

Results

We included 348 patients with ACRO-DM and 3480 with T2DM. Mean (SD) age was 60.3 (13.2) and 59.5 (15.6) years, whereas diabetes duration was 2.8 (5.8) and 3.0 (7.1) years in ACRO-DM and T2DM, respectively. Baseline cardiovascular morbidity was more common in ACRO-DM than T2DM group (61% vs 43%), including hypertension (48% vs 29%), heart failure (11% vs 5%), arrhythmia (13% vs 9%), and stroke (8% vs 5%). The hazard ratio (HR) for overall mortality was 1.18 (95% CI, 0.96-1.46) in ACRO-DM compared with T2DM group. The ACRO-DM group had a higher risk of cardiovascular morbidity (HR = 1.55; 95% CI, 1.24-1.94), with increased hazards for venous thromboembolism, specifically pulmonary, and arrhythmia, whereas cardiovascular mortality was not increased (HR = 1.12; 95% CI, 0.78-1.60).

Conclusion

The risk of cardiovascular morbidity was increased in patients with ACRO-DM compared to T2DM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcromegalyCardiovascular DiseasesDiabetes Mellitus, Type 2HumansFemaleSwedenMaleMiddle AgedRetrospective StudiesAgedRegistriesMorbidityFollow-Up Studies

Stichwörter der Autor:innen

acromegalycardiovasculardiabetesmorbiditymortalitytreatment

Autor:innen und Institutionen

  • Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy, University of Gothenburg, 413 46 Gothenburg, Sweden.
  • Department of Endocrinology, Sahlgrenska University Hospital, 413 46 Gothenburg, Sweden.
  • Wallenberg Center for Molecular and Translational Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden.
  • Endocrinology Unit, Department of Internal Medicine and Medical Specialties, School of Medical and Pharmaceutical Sciences, University of Genova, 16132 Genoa, Italy.
  • Endocrinology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
  • School of Public Health and Community Medicine, Institute of Medicine, University of Gothenburg, 413 20 Gothenburg, Sweden.

ORCID-Profile: Angelo Milioto, Martin Adiels, Annika Rosengren, Gudmundur Johannsson, Daniela Esposito

Förderung

  • ALF
  • Svenska Sällskapet för Medicinsk Forskning, Åke Wiberg Stiftelse
  • Göteborgs läkaresällskap
  • Svenska Läkaresällskapet
  • Swedish Research Council
  • Swedish Heart and Lung Foundation

Zitieren

APA

Milioto, A., Ragnarsson, O., Ferone, D., Adiels, M., Smith, J. G., Rosengren, A., Johannsson, G., & Esposito, D. (2026). Cardiovascular morbidity and mortality in acromegaly-associated diabetes: a Swedish nationwide study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag322

Vancouver

Milioto A, Ragnarsson O, Ferone D, Adiels M, Smith JG, Rosengren A, et al. Cardiovascular morbidity and mortality in acromegaly-associated diabetes: a Swedish nationwide study. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag322

BibTeX
@article{Milioto2026,
  author = {Milioto, Angelo and Ragnarsson, Oskar and Ferone, Diego and Adiels, Martin and Smith, J Gustav and Rosengren, Annika and Johannsson, Gudmundur and Esposito, Daniela},
  title = {Cardiovascular morbidity and mortality in acromegaly-associated diabetes: a Swedish nationwide study},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgag322}
}
Kostenlos starten →